NICE backs Veklury for treatment of COVID-19 in high-risk patients – The Pharma Letter

UK health technology assessor theNational Institute of Health and Care Excellence (NICE) has published final draft guidance recommending use of remdesivir for treating COVID-19 in eligible adults and children.

Marketed by US antivirals giant Gilead Sciences (Nasdaq: GILD) under the trade name Veklury, remdesivir was the first medicine for COVID-19 to receive full marketing authorization in 2022. However, as the pandemic receded, sales of the

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

Link:

NICE backs Veklury for treatment of COVID-19 in high-risk patients - The Pharma Letter

Related Posts
Tags: